|
1
|
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer.
|
Nat Genet
|
2012
|
5.64
|
|
2
|
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR.
|
Nature
|
2011
|
3.18
|
|
3
|
Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-small-cell lung cancer patients with EGFR mutations.
|
Clin Cancer Res
|
2011
|
3.15
|
|
4
|
A sensitive method for detecting EGFR mutations in non-small cell lung cancer samples with few tumor cells.
|
J Thorac Oncol
|
2008
|
1.30
|
|
5
|
Erlotinib resistance in lung cancer cells mediated by integrin β1/Src/Akt-driven bypass signaling.
|
Cancer Res
|
2013
|
1.23
|
|
6
|
KRAS mutations in lung cancer.
|
Clin Lung Cancer
|
2012
|
1.22
|
|
7
|
mRNA expression of BRCA1, PIAS1, and PIAS4 and survival after second-line docetaxel in advanced gastric cancer.
|
J Natl Cancer Inst
|
2011
|
1.14
|
|
8
|
Non-small-cell lung cancer harbouring mutations in the EGFR kinase domain.
|
Clin Transl Oncol
|
2010
|
1.10
|
|
9
|
Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.
|
Pharmacogenomics
|
2012
|
0.94
|
|
10
|
Fifth Educational Symposium of the Spanish Lung Cancer Group: report on the Molecular Biology Workshop.
|
Lung Cancer
|
2011
|
0.91
|
|
11
|
The predictive value of 53BP1 and BRCA1 mRNA expression in advanced non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy.
|
Oncotarget
|
2013
|
0.88
|
|
12
|
The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer.
|
PLoS One
|
2010
|
0.85
|
|
13
|
Methylation status of the p15, p16 and MGMT promoter genes in primary cutaneous T-cell lymphomas.
|
Haematologica
|
2004
|
0.84
|
|
14
|
HLA-G positive trophoblastic cells in transcervical samples and their isolation and analysis by laser microdissection and QF-PCR.
|
Prenat Diagn
|
2003
|
0.83
|
|
15
|
mRNA expression levels and genetic status of genes involved in the EGFR and NF-κB pathways in metastatic non-small-cell lung cancer patients.
|
J Transl Med
|
2011
|
0.82
|
|
16
|
Lymphomatoid papulosis associated with mycosis fungoides: clinicopathological and molecular studies of 12 cases.
|
Acta Derm Venereol
|
2004
|
0.82
|
|
17
|
Biomarkers in lung oncology.
|
Pulm Pharmacol Ther
|
2010
|
0.82
|
|
18
|
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
|
J Thorac Oncol
|
2013
|
0.77
|
|
19
|
Signaling pathways modulating dependence of lung cancer on mutant epidermal growth factor receptor and mechanisms of intrinsic and acquired resistance to tyrosine kinase inhibitors.
|
Curr Pharm Des
|
2014
|
0.76
|
|
20
|
Could the truncated variant of ERBB2 be present in the squamous carcinomas of the cervix?
|
Virchows Arch
|
2008
|
0.75
|
|
21
|
Analysis of T-cell receptor gamma gene rearrangements by PCR-Genescan and PCR-polyacrylamide gel electrophoresis in early-stage mycosis fungoides/large-plaque parapsoriasis.
|
Dermatology
|
2003
|
0.75
|
|
22
|
Comparative genomic hybridization analysis of cutaneous large B-cell lymphomas.
|
Exp Dermatol
|
2005
|
0.75
|